ATE522522T1 - Verfahren zur herstellung von als zwischenprodukte für die herstellung von modulatoren der chemokinrezeptoraktivität nützlichen verbindungen - Google Patents

Verfahren zur herstellung von als zwischenprodukte für die herstellung von modulatoren der chemokinrezeptoraktivität nützlichen verbindungen

Info

Publication number
ATE522522T1
ATE522522T1 AT10001989T AT10001989T ATE522522T1 AT E522522 T1 ATE522522 T1 AT E522522T1 AT 10001989 T AT10001989 T AT 10001989T AT 10001989 T AT10001989 T AT 10001989T AT E522522 T1 ATE522522 T1 AT E522522T1
Authority
AT
Austria
Prior art keywords
modulators
production
compounds useful
chemokine receptor
receptor activity
Prior art date
Application number
AT10001989T
Other languages
English (en)
Inventor
Michael Randazzo
Rulin Zhao
Boguslaw Mudryk
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE522522T1 publication Critical patent/ATE522522T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
AT10001989T 2006-07-28 2007-07-26 Verfahren zur herstellung von als zwischenprodukte für die herstellung von modulatoren der chemokinrezeptoraktivität nützlichen verbindungen ATE522522T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83423506P 2006-07-28 2006-07-28
US89602607P 2007-03-21 2007-03-21
US11/782,742 US7629351B2 (en) 2006-07-28 2007-07-25 N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process

Publications (1)

Publication Number Publication Date
ATE522522T1 true ATE522522T1 (de) 2011-09-15

Family

ID=38829183

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07813363T ATE509926T1 (de) 2006-07-28 2007-07-26 Modulatoren der chemokinrezeptoraktivität, kristalline formen und verfahren
AT10001989T ATE522522T1 (de) 2006-07-28 2007-07-26 Verfahren zur herstellung von als zwischenprodukte für die herstellung von modulatoren der chemokinrezeptoraktivität nützlichen verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07813363T ATE509926T1 (de) 2006-07-28 2007-07-26 Modulatoren der chemokinrezeptoraktivität, kristalline formen und verfahren

Country Status (26)

Country Link
US (2) US7629351B2 (de)
EP (2) EP2046779B1 (de)
JP (1) JP5236643B2 (de)
KR (1) KR20090033915A (de)
CN (1) CN101535301B (de)
AR (1) AR062124A1 (de)
AT (2) ATE509926T1 (de)
AU (1) AU2007279333B2 (de)
BR (1) BRPI0715415A2 (de)
CA (2) CA2659253A1 (de)
CY (1) CY1111744T1 (de)
DK (1) DK2046779T3 (de)
EA (1) EA016563B1 (de)
ES (1) ES2365264T3 (de)
HR (1) HRP20110465T1 (de)
IL (2) IL196427A (de)
MX (1) MX2009000808A (de)
NO (1) NO20090190L (de)
NZ (1) NZ574425A (de)
PE (1) PE20080732A1 (de)
PL (1) PL2046779T3 (de)
PT (1) PT2046779E (de)
SG (1) SG158924A1 (de)
SI (1) SI2046779T1 (de)
TW (2) TWI421249B (de)
WO (1) WO2008014360A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687508B2 (en) * 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US8383812B2 (en) * 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
KR20120135716A (ko) * 2011-06-07 2012-12-17 한미사이언스 주식회사 이중대칭 구조의 퀴나졸린 유도체 화합물 및 이의 용도
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
MA40320A (fr) * 2014-07-17 2017-05-24 Santen Pharmaceutical Co Ltd Agent prophylactique ou thérapeutique pour des troubles du segment postérieur de l'œil
BR112020000418A2 (pt) * 2017-07-20 2020-07-14 Bristol-Myers Squibb Company processo para a preparação de n-((1r,2s,5r)-5-(terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il) ciclo-hexil)acetamida
CN115677728A (zh) * 2022-11-02 2023-02-03 成都科岭源医药技术有限公司 一种海鞘素类化合物中间体的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6383082A (ja) 1986-09-26 1988-04-13 Takeda Chem Ind Ltd テトラヒドロフランカルボン酸誘導体の製造法
EP0550924A1 (de) 1991-12-16 1993-07-14 Merck & Co. Inc. 2-Pyrrolidinonderivate als Inhibitoren der HIV-Protease
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6054579A (en) 1997-06-26 2000-04-25 Leukosite, Inc. Synthesis of substituted lactams
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
WO1999037304A1 (en) 1998-01-27 1999-07-29 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
HUP0101329A3 (en) 1998-01-29 2002-07-29 Aventis Pharmaceuticals Inc Co Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compounds and a cyclyzed compounds there from
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6541208B1 (en) 1998-03-17 2003-04-01 University Of Maryland Biotechnology Institute Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
AU7354900A (en) 1999-09-09 2001-04-10 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
AR035773A1 (es) 2000-12-20 2004-07-14 Bristol Myers Squibb Pharma Co Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina
JP2005506949A (ja) 2000-12-20 2005-03-10 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体の調節剤としてのジアミン
EP1373494B1 (de) 2001-03-29 2006-03-01 Topo Target A/S Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii
GB0114867D0 (en) 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents
DE10135043A1 (de) 2001-07-11 2003-01-30 Bayer Cropscience Gmbh Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren
US7087604B2 (en) 2002-03-08 2006-08-08 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
US6835841B2 (en) 2002-09-13 2004-12-28 Bristol-Myers Squibb Company Asymmetric catalytic hydrogenation process for preparation of chiral cyclic β-aminoesters
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2004071449A2 (en) 2003-02-12 2004-08-26 Bristol-Myers Squibb Company Lactams as modulators of chemokine receptor activity
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US7291615B2 (en) 2003-05-01 2007-11-06 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20060205761A1 (en) 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
US7351720B2 (en) 2003-06-12 2008-04-01 Bristol-Myers Squibb Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US20050043392A1 (en) 2003-08-21 2005-02-24 Carter Percy H. Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7863317B2 (en) 2003-08-21 2011-01-04 Bristol-Myers Squibb Company Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
TWI354664B (en) * 2003-08-21 2011-12-21 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine rece
US7317019B2 (en) 2003-08-21 2008-01-08 Bristol Myers Squibb Co. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
BRPI0513953A (pt) 2004-07-30 2008-05-20 Pfizer Prod Inc métodos para tratamento de doenças ou distúrbios mediados pela ccr2
AU2005290028A1 (en) 2004-09-28 2006-04-06 Janssen Pharmaceutica, N.V. Substituted dipiperdine CCR2 antagonists
US7687508B2 (en) * 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
JP2009544756A (ja) 2009-12-17
US20100113489A1 (en) 2010-05-06
TW200821301A (en) 2008-05-16
EA016563B1 (ru) 2012-05-30
EP2046779B1 (de) 2011-05-18
US8049019B2 (en) 2011-11-01
ATE509926T1 (de) 2011-06-15
JP5236643B2 (ja) 2013-07-17
TWI421249B (zh) 2014-01-01
SG158924A1 (en) 2010-02-26
DK2046779T3 (da) 2011-09-05
EP2194051A1 (de) 2010-06-09
NZ574425A (en) 2011-11-25
US20080027084A1 (en) 2008-01-31
AU2007279333A1 (en) 2008-01-31
CN101535301B (zh) 2014-06-18
SI2046779T1 (sl) 2011-09-30
PT2046779E (pt) 2011-07-25
HRP20110465T1 (hr) 2011-07-31
NO20090190L (no) 2009-01-29
TW201414729A (zh) 2014-04-16
BRPI0715415A2 (pt) 2014-01-21
IL196427A (en) 2013-02-28
PE20080732A1 (es) 2008-06-13
ES2365264T3 (es) 2011-09-27
HK1130476A1 (en) 2009-12-31
PL2046779T3 (pl) 2011-09-30
US7629351B2 (en) 2009-12-08
WO2008014360A3 (en) 2008-12-31
CN101535301A (zh) 2009-09-16
IL206679A0 (en) 2010-12-30
AR062124A1 (es) 2008-10-15
IL196427A0 (en) 2009-09-22
KR20090033915A (ko) 2009-04-06
CA2831219A1 (en) 2008-01-31
EP2046779A2 (de) 2009-04-15
CA2659253A1 (en) 2008-01-31
CY1111744T1 (el) 2015-10-07
AU2007279333B2 (en) 2012-07-26
MX2009000808A (es) 2009-01-29
EP2194051B1 (de) 2011-08-31
WO2008014360A2 (en) 2008-01-31
EA200900245A1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
DE602006009845D1 (de) Verfahren zur herstellung von zwischenprodukten für die herstellung von ezetimibe
ATE522522T1 (de) Verfahren zur herstellung von als zwischenprodukte für die herstellung von modulatoren der chemokinrezeptoraktivität nützlichen verbindungen
DE602007013512D1 (de) Verfahren zur kontinuierlichen Herstellung von Bauteilen
EP2038375A4 (de) Verfahren zur herstellung von grundölen
EP2073636A4 (de) Verfahren für die herstellung von oxymorphon
DE502005010794D1 (de) Verfahren zur kontinuierlichen katalytischen Hydrierung
EP2271586A4 (de) Verfahren zur herstellung von kohlenstoffnanostrukturen
EP2100967A4 (de) Verfahren zur herstellung von lacto-n-biose i oder galacto-n-biose
DE502006007528D1 (de) Verfahren zur kontinuierlichen Herstellung von Kohlenstofffasern
DE502006005581D1 (de) Ukmischungen, ein verfahren zu deren herstellung, verfahren zur herstellung von verbund-formteilen und deren verwendung
DE602006014558D1 (de) Verbessertes verfahren für die herstellung von tee
EP2014783A4 (de) Verfahren zur herstellung von feuerverzinktem stahlblech und feuerverzinktes stahlblech
MY164700A (en) Method for producing coated molded bodies
DE602006004109D1 (de) Verbessertes Verfahren zur Herstellung von Schmierölen unter Verwendung von Doppelmetallcyanid-Katalysatoren
EP1916302A4 (de) Verfahren zur herstellung von lymphozyten
ATE498609T1 (de) Neues verfahren zur herstellung von für die synthese von vitamin-d-analoga geeigneten zwischenprodukten
DE502006001281D1 (de) Verfahren zur herstellung substituierter biphenyle
DE502006000036D1 (de) Kontinuierliches Verfahren zur Herstellung SiOC-enthaltender Verbindungen
DK2100871T3 (da) Katalytisk fremgangsmåde til fremstilling af mælkesyre af genanvendelige råmaterialer
EP2259269A4 (de) Verfahren zur herstellung von radiostrontium
DE112009001327A5 (de) Verfahren zur stereoselektiven Synthese von Phosphor-Verbindungen
DE602007001151D1 (de) Verfahren zur Herstellung laufmaschenfester Textilien
DE112009000076A5 (de) Verfahren zur Herstellung von Urethanen
ATE516253T1 (de) Verfahren zur herstellung eines zuschlagstoffs für die herstellung von baumaterialien
ATE507230T1 (de) Neues stereospezifisches verfahren zur herstellung von dioxabicyclooctan-verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties